

IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease

Among disclosures are:

RH for this study received travel support by Karolinska Institutet; is member of the IPECAD group (un-paid). RH outside this study received research grants from JPND, ZonMW, IMI, H2020 (paid to institution); received consulting fees in the past 3 years from Lilly Nederland (2023), iMTA (2023), and Biogen (2021) (paid to institution); is member of ISPOR special interest group open-source models (un-paid).

CG, PP-R and MU are employees and shareholders of Biogen.

Disclosures of other poster co-authors are not provided, they are available upon request.